Any drug therapy designed to promote calreticulin escape of ER retention to the plasma membrane can enhance tumor immunity and trigger CD91 calreticulin mediated tumor killing effects <a href=http://buycialis.homes>purchase cialis</a> Furthermore, the field is moving away from AI monotherapy as first line treatment for HR positive MBC, and research has now focused on combination therapy and ER targeting agents